SAFETY & SIDE EFFECTS

Safety of ZILBRYSQ in the 12-week clinical trial

The following side effects were experienced by 5% or more participants taking ZILBRYSQ and more frequently than those taking a placebo in the clinical trial:

Side effect

ZILBRYSQ

(86 participants)

Placebo

(88 participants)

Side effect
Injection site reactions
29%
16%
Upper respiratory tract infections
14%
7%
Diarrhea
11%
2%
Urinary tract infection
8%
5%
Nausea or vomiting
8%
7%
Lipase increased
7%
0%
Amylase increased
5%
1%
  • ZILBRYSQ increases your chance of getting serious meningococcal infections. Meningococcal infections may quickly become life-threatening or cause death if not recognized and treated early
    • You must receive vaccines for meningococcal infections at least 2 weeks before your first dose of ZILBRYSQ if you have not already received them
    • For more information about meningococcal vaccinations, click here
  • ZILBRYSQ may also increase the risk of other types of serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae
    • Certain people may be at risk of serious infections with gonorrhea. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and about regular testing
  • Pancreatitis and pancreatic cysts have happened in people who use ZILBRYSQ. Your healthcare provider will do blood tests to check your pancreas before you start treatment with ZILBRYSQ
  • No participants taking ZILBRYSQ stopped treatment due to injection site reaction

Long-term safety with ZILBRYSQ

The following side effects were experienced by participants in the ongoing long-term study.

Side effect

ZILBRYSQ

(200 participants)

Side effect
COVID-19
32%
Worsening myasthenia gravis
29%
Headache
20%
Nasopharyngitis
19.5%
Diarrhea
16.5%
Nausea
16%
Arthralgia
16%
Upper respiratory tract infection
16%
Fatigue
15%
Pancreatitis
1.9%
Pancreatic cysts
1.4%

Safety data was collected on May 11, 2023.

  • Side effects seen in the ongoing long-term study were similar to those seen in the 12-week clinical trial
  • 9.5% of participants stopped taking ZILBRYSQ due to side effects*
  • In the long-term study, 5% (10 of 213) of participants showed signs of morphea (a skin condition that causes painless, discolored patches on the skin, which may become firm, dry, and smooth over time)
    • Most cases had a time to onset longer than one year after start of treatment and were mild to moderate in severity
    • One participant stopped taking ZILBRYSQ due to morphea

*At the time of data collection, participants were taking ZILBRYSQ for a median of 1.8 years (0.11–5.1 years).

Doctor Discussion Guide.

Ask your doctor about ZILBRYSQ

Our Doctor Discussion Guide can help you get the conversation started.

Doctor Discussion Guide